Collecting Long-Term Outcomes in Population-Based Cancer Registry Data: The Case of Breast Cancer Recurrence.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
Oct 2024
Historique:
medline: 1 11 2024
pubmed: 1 11 2024
entrez: 31 10 2024
Statut: ppublish

Résumé

Cancer recurrence is an important long-term outcome of cancer survivors that is often not routinely collected and recorded by population-based registries. In this study, we review population-based studies to determine the current availability, landscape, and infrastructure of long-term outcomes, particularly metastatic recurrence, in women initially diagnosed with nonmetastatic breast cancer (MBC). We reviewed the literature to identify studies that used population-based registry data to examine the distribution of metastatic recurrence in women diagnosed with non-MBC. Data on outcomes and methods of ascertainment were extracted. Registry infrastructure including sources and funding was also reviewed. A total of 23 studies from 11 registries in eight countries spanning Europe, North America, and Oceania were identified and included in the review. Most studies were retrospective in nature and collected recurrence data only for ad hoc studies rather than as part of their routine registration. Definition of recurrence and data sources varied considerably across studies: the cancer-free time interval between the start of follow-up and risk window ranged from the diagnosis of primary tumor (n = 7) to 6 months from diagnosis (n = 1); the start of follow-up differed between initial diagnosis (n = 16) and treatment (n = 7). Cancer surveillance should encompass outcomes among survivors for research and monitoring. Studies are underway, but more are needed. Cancer registries should be supported to routinely collect recurrence data to allow complete evaluation of MBC as an outcome to be conducted and inform health care providers and researchers of the prognosis of both nonmetastatic and metastatic patients with breast cancer.

Identifiants

pubmed: 39481072
doi: 10.1200/GO-24-00249
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2400249

Auteurs

Eileen Morgan (E)

Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Colette O'Neill (C)

National Cancer Registry Ireland, Cork, Ireland.

Aude Bardot (A)

Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Paul Walsh (P)

National Cancer Registry Ireland, Cork, Ireland.

Ryan R Woods (RR)

BC Cancer, Vancouver, Canada.

Lou Gonsalves (L)

Department of Public Health, Connecticut Tumor Registry, State of Connecticut, Hartfort, CT.

Sinéad Hawkins (S)

Northern Ireland Cancer Registry (NICR), Centre for Public Health, Queen's University, Belfast, the United Kingdom.

Jan F Nygård (JF)

Cancer Registry of Norway, Norwegian Institute of Public Health NO, Oslo, Norway.

Serban Negoita (S)

Data Quality, Analysis, and Interpretation Branch, Division of Cancer Control and Population Sciences, Surveillance Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Esmeralda Ramirez-Pena (E)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.

Karen Gelmon (K)

BC Cancer, Vancouver, Canada.

Sabine Siesling (S)

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands.

Fatima Cardoso (F)

Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and ABC Global Alliance, Lisbon, Portugal.

Julie Gralow (J)

American Society of Clinical Oncology, Alexandria, VA.

Isabelle Soerjomataram (I)

Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Melina Arnold (M)

Cancer Surveillance Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH